Healthcare Asia’s business portfolio consists of a wide array of products in different oncology areas, stemming from its strong partnerships with suppliers in Europe and United States. Healthcare Asia monitors the list of new FDA-approved drugs closely to keep up with the ever-changing environment of the pharmaceutical industry.

The extensive range includes drugs such as but not limited to:

  • Bladder Cancer Drugs

  • Bone Cancer Drugs

  • Breast Cancer Drugs

  • Leukemia Drugs

  • Liver Cancer Drugs

  • Lung Cancer Drugs

  • Prostate Cancer Drugs

  • Rhabdomyosarcoma Drugs

  • Skin Cancer Drugs

  • Soft Tissue Sarcoma Drugs

  • Thyroid Cancer Drugs

  • Non Small Cell Cancer Drugs

  • Newly approved FDA / EMA Drugs